The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol

The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol

Bibliographic Details
Main Author:	Dong-Ryeol Ryu
Format:	Article
Language:	English
Published:	The Korean Society of Nephrology 2017-09-01
Series:	Kidney Research and Clinical Practice
Online Access:	https://doi.org/10.23876/j.krcp.2017.36.3.207

Similar Items

Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat
by: Andreas Jordan, et al.
Published: (2018-05-01)

The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2
by: Yoshiki Higa, et al.
Published: (2023-01-01)

Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis
by: Sollip Kim, et al.
Published: (2017-09-01)

Xanthine oxidase and aldehyde oxidase contribute to allopurinol metabolism in rats
by: Yoshitaka Tayama, et al.
Published: (2022-12-01)

Febuxostat, a Xanthine Oxidase Inhibitor, Decreased Macrophage Matrix Metalloproteinase Expression in Hypoxia
by: Shuoyu Wei, et al.
Published: (2020-11-01)

Comparison of Xanthine Oxidase Inhibitory Effect of Swertia chirayita and Febuxostat in Vitro
by: Qura-Tul-Ain, et al.
Published: (2021-04-01)

Inhibition mechanism of baicalein and baicalin on xanthine oxidase and their synergistic effect with allopurinol
by: Ni Zeng, et al.
Published: (2018-11-01)

Discovery of Novel Allopurinol Derivatives with Anticancer Activity and Attenuated Xanthine Oxidase Inhibition
by: Yong Li, et al.
Published: (2016-06-01)

Ten Years Milestones in Xanthine Oxidase Inhibitors Discovery: Febuxostat-Based Inhibitors Trends, Bifunctional Derivatives, and Automatized Screening Assays
by: Miguel F. S. de Abreu, et al.
Published: (2022-10-01)

Effects of Allopurinol as a xanthine oxidase inhibitor on depressive-like behavior of rats and changes in serum BDNF level
by: Mahsa Hadipour Jahromy, et al.
Published: (2022-12-01)

Inhibition of xanthine oxidase by allopurinol suppresses HMGB1 secretion and ameliorates experimental asthma
by: Yanhong Wang, et al.
Published: (2024-04-01)

Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice
by: Maimaiti Yisireyili, et al.
Published: (2017-04-01)

Xanthine Oxidase Inhibitor Allopurinol Prevents Oxidative Stress‐Mediated Atrial Remodeling in Alloxan‐Induced Diabetes Mellitus Rabbits
by: Yajuan Yang, et al.
Published: (2018-05-01)

Renoprotective impact of allopurinol in elderly patients with hypertension
by: Peyman Mottaghi
Published: (2018-04-01)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
by: Dimitrios Patoulias, et al.
Published: (2021-12-01)

Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol
by: Ajinkya Pawar, et al.
Published: (2021-04-01)

Effects of Cherry in Take Versus Allopurinol on Serum Uric Acid Levels, Biomarkers of Oxidative Stress and Hepatic Xanthine Oxidase/Xanthine Dehydrogenase Activity in Hyperuricemic Rats
by: F Haidari
Published: (2012-05-01)

Effects of Cherry in Take Versus Allopurinol on Serum Uric Acid Levels, Biomarkers of Oxidative Stress and Hepatic Xanthine Oxidase/Xanthine Dehydrogenase Activity in Hyperuricemic Rats
by: F. Haidari, et al.
Published: (2008-07-01)

Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK.
by: Johji Nomura, et al.
Published: (2013-01-01)

Effect of Febuxostat versus Allopurinol on the Glomerular Filtration Rate and Hyperuricemia in Patients with Chronic Kidney Disease
by: Shankar Prasad Nagaraju, et al.
Published: (2023-01-01)

Xanthine oxidase inhibitors treatment or discontinuation effects on mortality: evidence of xanthine oxidase inhibitors withdrawal syndrome
by: Masanari Kuwabara, et al.
Published: (2024-01-01)

Xanthine oxidase inhibitors in asymptomatic hyperuricemia
by: O. V. Zhelyabina, et al.
Published: (2019-10-01)

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
by: Xudong Guan, et al.
Published: (2022-09-01)

African American patients with gout: efficacy and safety of febuxostat vs allopurinol
by: Wells Alvin F, et al.
Published: (2012-02-01)

Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression
by: Seokwoo Park, et al.
Published: (2022-01-01)

Long-term inhibition of xanthine oxidase by febuxostat does not decrease blood pressure in deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
by: Theodora Szasz, et al.
Published: (2013-01-01)

Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients
by: Ching-Lan Cheng, et al.
Published: (2022-08-01)

Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study
by: Amayelle Rey, et al.
Published: (2019-11-01)

Some opportunities of using xanthine oxidase inhibitors
by: O. V. Zhelyabina, et al.
Published: (2019-03-01)

Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis
by: Jasvinder A. Singh, et al.
Published: (2018-08-01)

Screening of Xanthine Oxidase inhibitor from potential Malaysian medicinal plants
by: Jamal, Parveen, et al.
Published: (2010)

Study of potential xanthine oxidase inhibitors: In silico and in vitro biological activity
by: Muthuswamy Umamaheswari, et al.
Published: (2011-12-01)

Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients
by: Yanchun Li, et al.
Published: (2019-01-01)

Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta‐analysis
by: Jian‐hao Deng, et al.
Published: (2024-03-01)

Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Amani Al-Shargi, et al.
Published: (2023-11-01)

A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout
by: Fengchun Zhang, et al.
Published: (2019-09-01)

DESIGN AND PREPARATION SET OF COMPOUNDS AS INHIBITOR OF XANTHINE OXIDASE
by: BILAL MOHAMMED, et al.
Published: (2017-05-01)

Structure–Activity Relationship of Xanthones as Inhibitors of Xanthine Oxidase
by: Ling-Yun Zhou, et al.
Published: (2018-02-01)

Inhibition of xanthine oxidase by allopurinol prevents skeletal muscle atrophy: role of p38 MAPKinase and E3 ubiquitin ligases.
by: Frederic Derbre, et al.
Published: (2012-01-01)

Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System
by: Yang Bai, et al.
Published: (2023-09-01)